This inventor holds 1 USPTO granted patent. Top assignees: Fundación Para La Investigación Del Hospital Universitario La Fe De La Comunidad Valenciana, Maastricht University. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2 
1 out of 7 Years Active: 2024
Title: The Innovative Contributions of Stephane Heymans
Introduction
Stephane Heymans is a notable inventor based in Maastricht, Netherlands. He has made significant contributions to the field of medical research, particularly in predicting cardiotoxicity risk in cancer patients undergoing chemotherapy. His innovative approach combines advanced biological techniques with clinical applications, showcasing his dedication to improving patient outcomes.
Latest Patents
Stephane Heymans holds a patent for a groundbreaking invention titled "Predicting cardiotoxicity risk in cancer patients receiving anthracyclines chemotherapy." This invention refers to an in vitro method for predicting the risk of cardiotoxicity in cancer patients based on the expression levels of a combination of 10 circulating miRNAs. These miRNAs include miRNA 16-5p, miRNA 22-3p, miRNA 30b-5p/30c-5p, miRNA 92b-3p, miRNA 148a-3p, miRNA-150-5p, miRNA-192-5p, miRNA 215-5p, miRNA 486-3p/486-5p, and miRNA-4732-3p. The invention also identifies this set of miRNAs as a biomarker for predicting cardiotoxicity risk in patients receiving anthracyclines chemotherapy. Furthermore, it contemplates a method for preventing cardiotoxicity by modulating the expression levels of these miRNAs.
Career Highlights
Throughout his career, Stephane Heymans has worked with esteemed institutions such as the Fundación para la Investigación del Hospital Universitario La Fe de la Comunidad Valenciana and Maastricht University. His work has been instrumental in advancing research in the field of oncology and cardiology.
Collaborations
Stephane has collaborated with notable colleagues, including David Hervàs Marin and Ana Santaballa Beltràn. These partnerships have contributed to the success of his research and the development of his innovative patent.
Conclusion
Stephane Heymans exemplifies the spirit of innovation in medical research, particularly in the area of cancer treatment. His patent for predicting cardiotoxicity risk represents a significant advancement in patient care and highlights the importance of ongoing research in this critical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile